Novel therapeutic strategy for human epidermal growth factor receptor 2-positive gastric cancer

Nobuhiko Kanaya, Shinji Kuroda, Tetsushi Kubota, Toshiaki Morihiro, Satoru Kikuchi, Masahiko Nishizaki, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

Research output: Contribution to journalReview articlepeer-review

3 Citations (Scopus)


Trastuzumab (Tmab), a humanized monoclonal antibody that selectively targets human epidermal growth factor receptor 2 (HER2), is currently used in the clinical setting for the treatment of both breast and gastric cancer. While Tmab has shown improvements in patient prognoses, acquired resistance to this agent remains an issue. While some novel HER2-targeted agents have been approved for clinical use in breast cancer, no such agent has shown treatment efficacy for gastric malignancies with Tmab-resistance. Nanotechnology, which has progressed rapidly, has been applied to medical fields in recent years. Gold nanopartides, which are characterized by their in vivo stability and ease of surface modification, have been reported to show efficacy as the carriers of therapeutic agents, such as drugs, antibodies, peptides, and nucleic acids. In this work, we developed Tmab-conjugated gold nanopartides and demonstrate their efficacy for the treatment of HER2-positive, Tmab-resistant gastric cancer cell lines. Our findings demonstrate that Tmab-conjugated gold nanopartides have the potential to be a novel HER2-targeted therapeutic agent.

Original languageEnglish
Pages (from-to)883-885
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Issue number10
Publication statusPublished - Oct 2017


  • Gastric cancer
  • Human epidermal growth factor receptor 2 (HER2)
  • Trastuzumab

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Novel therapeutic strategy for human epidermal growth factor receptor 2-positive gastric cancer'. Together they form a unique fingerprint.

Cite this